Medpace Holdings, Inc.

Equities

MEDP

US58506Q1094

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-06-21 EDT 5-day change 1st Jan Change
404 USD +0.85% Intraday chart for Medpace Holdings, Inc. +2.57% +31.81%

This article is for Premium subscribers only

Signed up already?

Log In

Not subscribed yet?

Subscribe

The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
Surperformance is Buy on MEDPACE HOLDINGS, INC. since 2022-06-06 .

Medpace Holdings Insider Sold Shares Worth $3,081,617, According to a Recent SEC Filing MT
Medpace Holdings Insider Sold Shares Worth $3,828,058, According to a Recent SEC Filing MT
TD Cowen Starts Medpace Holdings With Buy Rating, $452 Price Target MT
Mizuho Starts Medpace Holdings With Buy Rating, $435 Price Target MT
Medpace Holdings Insider Sold Shares Worth $1,608,764, According to a Recent SEC Filing MT
Medpace Holdings Insider Sold Shares Worth $15,924,222, According to a Recent SEC Filing MT
Medpace Holdings Insider Sold Shares Worth $1,996,723, According to a Recent SEC Filing MT
Medpace Holdings Insider Sold Shares Worth $21,129,347, According to a Recent SEC Filing MT
Medpace Holdings Insider Sold Shares Worth $6,553,671, According to a Recent SEC Filing MT
Medpace Holdings Insider Sold Shares Worth $6,782,987, According to a Recent SEC Filing MT
Baird Adjusts Medpace Price Target to $454 From $446, Maintains Outperform Rating MT
Transcript : Medpace Holdings, Inc., Q1 2024 Earnings Call, Apr 23, 2024
Jefferies Upgrades Medpace Holdings to Buy, Price Target at $450 MT
Medpace Q1 Earnings, Revenue Rise; Updates 2024 Guidance MT
Medpace Guides For FY 2024 GAAP EPS of $10.79-$11.47 on Revenue of $2.15-$2.2 Billion, vs CIQ Analyst Consensus of $10.57/Share on Revenue of $2.18 Billion MT
Earnings Flash (MEDP) MEDPACE HOLDINGS Posts Q1 Revenue $511M, vs. Street Est of $512M MT
Tranche Update on Medpace Holdings, Inc.'s Equity Buyback Plan announced on October 24, 2022. CI
Medpace Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 CI
North American Morning Briefing : Stock Futures -2- DJ
Deutsche Bank Initiates Coverage on Medpace With Hold Rating, $395 Price Target MT
Medpace Holdings Insider Sold Shares Worth $82,321,250, According to a Recent SEC Filing MT
UBS Adjusts Medpace Price Target to $480 From $452, Maintains Buy Rating MT
Medpace Holdings Insider Sold Shares Worth $8,996,033, According to a Recent SEC Filing MT
Medpace Holdings Insider Sold Shares Worth $40,291,000, According to a Recent SEC Filing MT
Chart Medpace Holdings, Inc.
More charts
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
404 USD
Average target price
429 USD
Spread / Average Target
+6.19%
Consensus
  1. Stock Market
  2. Equities
  3. MEDP Stock
  4. News Medpace Holdings, Inc.
  5. Medpace Holdings, Inc: A winning stock that went under the radar